On Monday, Shares of Intel Corporation (NASDAQ:INTC), gained 1.27% to $33.41.
Altera got a rather pointed message last week from some of its shareholders who think the chip maker was crazy to turn down a stated $16 billion offer from Intel, according to WSJ.
Altera , spiked Monday after reports Intel (INTC) is interested in resuming buyout talks with its rival.
Intel Corporation designs, manufactures, and sells integrated digital technology platforms worldwide. It operates through PC Client Group, Data Center Group, Internet of Things Group, Mobile and Communications Group, Software and Services, and All Other segments.
Shares of Gilead Sciences Inc. (NASDAQ:GILD), inclined 1.56% to $111, during its last trading session.
Gilead Sciences, declared that its corporate presentation will be webcast from the UBS 2015 Global Healthcare Conference in New York.
Robin Washington, Gilead’s Executive Vice President and Chief Financial Officer, will provide an overview of the company at the conference on Tuesday, May 19 at 10:00 a.m. Eastern Time.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific. The companys products comprise Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease.
At the end of Monday’s trade, Shares of Alcatel-Lucent (NYSE:ALU), gained 0.27% to $3.77.
Today, Alcatel-Lucent, has signed a memorandum of understanding with South Korean telecommunications provider, KT, under which the companies will collaborate to test technologies for the eventual introduction of 5G mobile networks and infrastructure capable of meeting the huge connectivity demands predictable in the future.
The partnership will initially focus on Alcatel-Lucent’s virtualized Radio Access Network (vRAN) technology. At Mobile World Congress this year, Alcatel-Lucent demonstrated how its vRAN capability could assist operators dynamically meet changing customer, market and environmental demands while enhancing network performance and lowering costs.
Alcatel-Lucent provides Internet protocol (IP) and cloud networking, and ultra- broadband access worldwide. The company’s Core Networking segment offers IP routing, carrier Ethernet, network functions virtualization, and software defined networking applications and infrastructure to meet the challenges of network traffic growth while supporting the delivery of cloud-enabled business, mobile, and residential services for service providers, mobile network operators, cable/multiple system operators, transportation, utilities, and large-scale enterprises.
Finally, AbbVie Inc. (NYSE:ABBV), ended its last trade with -0.58% loss, and closed at $65.61.
AbbVie, declared that the U.S. Food and Drug Administration (FDA) has granted HUMIRA® (adalimumab) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hurley Stage III disease), a painful, chronic inflammatory skin disease. AbbVie’s supplemental Biologic License Application seeking FDA approval for the use of HUMIRA in patients with moderate-to-severe HS is presently under review with the agency. HUMIRA is not presently approved by regulatory authorities for the treatment of HS.
HS, sometimes referred to as “acne inversa” by dermatologists, is a painful, chronic inflammatory skin disease for which there is no known cure and no approved medication. The disease is characterized by inflamed areas typically located around the armpits and groin, between the buttocks and under the breasts. A number of physical signs are associated with HS – namely, painful abscesses and nodules, sinus tracts and scarring. The symptoms associated with HS may lead to limited movement and psychological strain that impact the lives of patients.
Physicians typically assess the signs and symptoms of HS on a scale developed from a clinical measure of severity called the Hurley Staging System. Hurley Stage II manifests with recurrent abscesses with sinus tracts and scarring, single or multiple widely separated lesions. In Hurley Stage III, patients present with either spread or interconnected abscesses.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
